AYTU BIOPHARMA, INC 8-K

What Happened

• Aytu BioPharma, Inc. announced that it and Lannett Company, Inc. mutually agreed to terminate the exclusive Metadate license agreement, effective June 23, 2026. The original license was dated May 11, 2022 and had amendments on July 6, 2023 and July 17, 2025.
• The parties executed a Termination Agreement that ends the Metadate Agreement in its entirety except for specified provisions that survive termination. Aytu may continue to sell and distribute existing Metadate inventory at its discretion and must continue to provide royalty reports and pay royalties until those sales stop.
• Net revenue for Metadate CD® reported by Aytu for the quarter ended March 31, 2026 was $49,000. The full Termination Agreement text will be filed as an exhibit to Aytu’s Form 10-K for the year ended June 30, 2026.

Key Details

• Termination date: June 23, 2026 (mutual agreement between Aytu and Lannett).
• Original Metadate Agreement: entered May 11, 2022; amended July 6, 2023 and July 17, 2025.
• Short-term sales: Aytu may continue selling existing Metadate inventory and must report/pay royalties until sales cease.
• Reported Metadate revenue: $49,000 for quarter ended March 31, 2026.
• Document availability: Termination Agreement will be attached to Aytu’s 2026 Form 10-K.

Why It Matters

• This termination ends the active licensing relationship around the Metadate product, which may limit any future product development or joint commercialization tied to that agreement.
• The financial impact disclosed so far appears limited: Metadate generated modest revenue ($49K) in the most recent quarter, and Aytu can still derive short-term revenue from existing inventory while continuing royalty obligations.
• Investors should review the Termination Agreement (to be filed with the 10-K) for details on surviving obligations, indemnities, and any other provisions that could affect future cash flows or liabilities.